A
Ann-Mari Svennerholm
Researcher at University of Gothenburg
Publications - 16
Citations - 348
Ann-Mari Svennerholm is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Enterotoxigenic Escherichia coli & Antigen. The author has an hindex of 9, co-authored 16 publications receiving 224 citations.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trial
Firdausi Qadri,Marjahan Akhtar,Taufiqur Rahman Bhuiyan,Mohiul I. Chowdhury,Tasnuva Ahmed,Tanzeem Ahmed Rafique,Arifuzzaman Khan,Sadia Isfat Ara Rahman,Farhana Khanam,Anna Lundgren,Gudrun Wiklund,Joanna Kaim,Madeleine Löfstrand,Nils Carlin,A. Louis Bourgeois,Nicole Maier,Alan Fix,Thomas F. Wierzba,Richard I. Walker,Ann-Mari Svennerholm +19 more
TL;DR: The encouraging safety and immunogenicity of ETVAX and benefit of dmLT adjuvant in young children support its further assessment for protective efficacy in children in enterotoxigenic E coli-endemic areas.
Journal ArticleDOI
Colonization factors among enterotoxigenic Escherichia coli isolates from children with moderate-to-severe diarrhea and from matched controls in the Global Enteric Multicenter Study (GEMS).
Roberto Vidal,Khitam Muhsen,Sharon M. Tennant,Ann-Mari Svennerholm,Samba O. Sow,Dipika Sur,Anita K. M. Zaidi,Abu Syed Golam Faruque,Debasish Saha,Richard A. Adegbola,M. Jahangir Hossain,Pedro L. Alonso,Robert F. Breiman,Quique Bassat,Boubou Tamboura,Doh Sanogo,Uma Onwuchekwa,Byomkesh Manna,Thandavarayan Ramamurthy,Suman Kanungo,Shahnawaz Ahmed,Shahida Qureshi,Farheen Quadri,Anowar Hossain,Sumon Kumar Das,Martin Antonio,Inacio Mandomando,Tacilta Nhampossa,Sozinho Acácio,Richard Omore,John B. Ochieng,Joseph Oundo,Eric D. Mintz,Ciara E. O’Reilly,Lynette Y. Berkeley,Sofie Livio,Sandra Panchalingam,Dilruba Nasrin,Tamer H. Farag,Yukun Wu,Halvor Sommerfelt,Halvor Sommerfelt,Roy M. Robins-Browne,Felipe Del Canto,Tracy H. Hazen,David A. Rasko,Karen L. Kotloff,James P. Nataro,Myron M. Levine +48 more
TL;DR: Major CF-based efficacious ETEC vaccines could potentially prevent up to 66% of pediatric MSD cases due to ST-encoding ETEC in developing countries; adding CS14 extends coverage to ~77%.
Journal ArticleDOI
Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.
Marjahan Akhtar,Mohiul I. Chowdhury,Taufiqur Rahman Bhuiyan,Joanna Kaim,Tasnuva Ahmed,Tanzeem Ahmed Rafique,Arifuzzaman Khan,Sadia Isfat Ara Rahman,Farhana Khanam,Yasmin Ara Begum,Mir Z. Sharif,Laila N. Islam,Nils Carlin,Nicole Maier,Alan Fix,Thomas F. Wierzba,Richard I. Walker,A. Louis Bourgeois,Ann-Mari Svennerholm,Firdausi Qadri,Anna Lundgren +20 more
TL;DR: The killed oral ETEC vaccine ETVAX ± dmLT adjuvant was safe in Bangladeshi adults and ALS responses measured by electrochemiluminescence and ELISA assays correlated well.
Journal ArticleDOI
Identification of new heat-stable (STa) enterotoxin allele variants produced by human enterotoxigenic Escherichia coli (ETEC).
Enrique Joffré,Enrique Joffré,Astrid von Mentzer,Astrid von Mentzer,Ann-Mari Svennerholm,Åsa Sjöling +5 more
TL;DR: It is found that the ETEC isolates producing the most common STp variant, STa5, co-expressed coli surface antigen CS6 and was significantly associated with disease in adults in this data set and may suggest differences in pathogenicity of ETEC in children and adult populations.
Journal ArticleDOI
Cross-reactivity and avidity of antibody responses induced in humans by the oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine ETVAX
TL;DR: The results suggest that the cross-reactive antibody responses against multiple CFs may result in expanded ETEC strain coverage of ETVAX and that repeated vaccinations induce vaccine-specific antibodies with increased binding capacity.